(Q38594410)

4 September 2017

title

Lyme borreliosis: reviewing potential vaccines, clinical aspects and health economics (English)

1 reference

4 September 2017

0 references

language of work or name

1 reference

28 September 2015

1 reference

Expert Review of Vaccines

4 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26414102%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26414102%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26414102%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

page(s)

1549-1561

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26414102%20AND%20SRC:MED&resulttype=core&format=json

Erythema chronicum migrans and Lyme arthritis. The enlarging clinical spectrum

3 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

The expanding Lyme Borrelia complex—clinical significance of genomic species?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Borrelia valaisiana in cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Vasculitis-like syndrome associated with Borrelia lusitaniae infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Detection of Borrelia bissettii in Cardiac Valve Tissue of a Patient with Endocarditis and Aortic Valve Stenosis in the Czech Republic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

A new Borrelia species defined by multilocus sequence analysis of housekeeping genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Lyme Disease—European Perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Association between different clinical manifestations of Lyme disease and different species of Borrelia burgdorferi sensu lato

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Borrelia burgdorferi sensu lato and Ehrlichia spp. in Ixodes ticks from southern Norway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Determination of novel Borrelia genospecies in Swedish Ixodes ricinus ticks

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Identification of Ehrlichia spp. and Borrelia burgdorferi in Ixodes ticks in the Baltic regions of Russia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

A Novel multivalent OspA vaccine against Lyme borreliosis is safe and immunogenic in an adult population previously infected with Borrelia burgdorferi sensu lato

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

The cost effectiveness of vaccinating against Lyme disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

The cost-effectiveness of vaccination against Lyme disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Cost-effectiveness analysis of the Lyme disease vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Vaccines against Lyme disease: What happened and what lessons can we learn?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Relationship between immunity to Borrelia burgdorferi outer-surface protein A (OspA) and Lyme arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Human Lyme disease vaccines: past and future concerns.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Design and development of a novel vaccine for protection against Lyme borreliosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Increased incidence of Lyme borreliosis in southern Sweden following mild winters and during warm, humid summers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Epidemiological situation of Lyme borreliosis in germany: surveillance data from six Eastern German States, 2002 to 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Lyme disease surveillance in England and Wales, 1986 1998.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Increasing geographical distribution and density of Ixodes ricinus (Acari: Ixodidae) in central and northern Sweden.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Clinical distinction between human granulocytic ehrlichiosis and the initial phase of tick-borne encephalitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Concomitant infection with tick-borne encephalitis virus and Borrelia burgdorferi sensu lato in patients with acute meningitis or meningoencephalitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Concurrent Lyme disease and babesiosis. Evidence for increased severity and duration of illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Characterization of Lyme borreliosis isolates from patients with erythema migrans and neuroborreliosis in southern Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Lyme disease: laboratory issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Prospective study of serologic tests for lyme disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

ELISA-based measurement of antibody responses and PCR-based detection profiles can distinguish between active infection and early clearance of Borrelia burgdorferi

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Positive Lyme disease serology in patients with clinical and laboratory evidence of human granulocytic ehrlichiosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Diagnosis of lyme borreliosis in europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Validation of cultivation and PCR methods for diagnosis of Lyme neuroborreliosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Diagnosis of lyme borreliosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Natural killer cell counts are not different between patients with post-Lyme disease syndrome and controls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Lyme disease: diagnostic issues and controversies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Long-term clinical outcome after Lyme neuroborreliosis in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Chronic neurologic manifestations of erythema migrans borreliosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Clinical courses of acute and chronic neuroborreliosis following treatment with ceftriaxone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Skin manifestations of lyme borreliosis: diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Therapy for Lyme arthritis: strategies for the treatment of antibiotic-refractory arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Cognitive function in post-treatment Lyme disease: do additional antibiotics help?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Two Controlled Trials of Antibiotic Treatment in Patients with Persistent Symptoms and a History of Lyme Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

A Critical Appraisal of “Chronic Lyme Disease”

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Treatment trials for post-Lyme disease symptoms revisited.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Persistence of Borrelia burgdorferi in rhesus macaques following antibiotic treatment of disseminated infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Antibiotic treatment of animals infected with Borrelia burgdorferi

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Differentiation of reinfection from relapse in recurrent Lyme disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Reinfection in patients with Lyme disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Lyme borreliosis vaccination: the facts, the challenge, the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Molecular analysis of linear plasmid-encoded major surface proteins, OspA and OspB, of the Lyme disease spirochaete Borrelia burgdorferi

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Molecular analysis and expression of a Borrelia burgdorferi gene encoding a 22 kDa protein (pC) in Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Disulfide-mediated oligomer formation in Borrelia burgdorferi outer surface protein C, a critical virulence factor and potential Lyme disease vaccine candidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Vaccination against Lyme disease: past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Monoclonal antibodies specific for the outer surface protein A (OspA) of Borrelia burgdorferi prevent Lyme borreliosis in severe combined immunodeficiency (scid) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Borrelia burgdorferi OspA is an arthropod-specific transmission-blocking Lyme disease vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Safety and immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against lyme disease in healthy children and adolescents: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Correcting a public health fiasco: The need for a new vaccine against Lyme disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Construction and analysis of variants of a polyvalent Lyme disease vaccine: approaches for improving the immune response to chimeric vaccinogens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

An Octavalent Lyme Disease Vaccine Induces Antibodies That Recognize All Incorporated ospC Type-Specific Sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Development of an OspC-based tetravalent, recombinant, chimeric vaccinogen that elicits bactericidal antibody against diverse Lyme disease spirochete strains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

The cost-effectiveness of vaccinating against Lyme disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

Three Major Lyme Borrelia Genospecies (Borrelia burgdorferi sensu stricto, B. afzelii and B. garinii) Identified by PCR in Cerebrospinal Fluid from Patients with Neuroborreliosis in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1091313

10.1586/14760584.2015.1091313

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26414102%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

1 reference